36 results on '"Lev, Paola R."'
Search Results
2. Megakaryocyte–stromal cell interactions: Effect on megakaryocyte proliferation, proplatelet production, and survival
3. Elevated levels of damageassociated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis.
4. Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis.
5. High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis
6. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status
7. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia
8. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus
9. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count
10. Pathogenic mechanisms contributing to thrombocytopenia in patients with systemic lupus erythematosus.
11. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia
12. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets
13. Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia
14. Normal platelets possess the soluble form of IL-6 receptor
15. JAK2 V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status
16. Publisher Correction: Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia
17. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia
18. Autoantibodies in immune thrombocytopenia affect the physiological interaction between megakaryocytes and bone marrow extracellular matrix proteins
19. Differential expression of SDF-1 receptor CXCR4 in molecularly defined forms of inherited thrombocytopenias
20. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms
21. Platelet Apoptosis in Adult Immune Thrombocytopenia: Insights into the Mechanism of Damage Triggered by Auto-Antibodies
22. Correction: Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients
23. Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients
24. Autoantibodies in immune thrombocytopenia affect the physiological interaction between megakaryocytes and bone marrow extracellular matrix proteins.
25. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according toJAK2/CALR/MPLmutational status
26. Differential expression of SDF-1 receptor CXCR4 in molecularly defined forms of inherited thrombocytopenias.
27. Platelet Apoptosis in Adult Immune Thrombocytopenia. Relationship with Auto-Antibodies, Platelet Function and Treatment
28. Screening forMPLmutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation inMPLW515L-positive platelets
29. Screening for MPL mutations in Essential Thrombocythemia and Primary Myelofibrosis: Normal Mpl Expression and Absence of Constitutive STAT3 and STAT5 Activation in MPLW515L-Positive Platelets.
30. Anti-Apoptotic Effect of Soluble IL-6 Receptor on Megakaryocytic Lineage in Physiologic Conditions and Essential Thrombocythemia.
31. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status
32. Frequency of the JAK2V617F Mutation in Platelets from Essential Thrombocythemia (ET) Patients.
33. Follow-Up of Clinical Manifestations and Platelet Function Test in Patients with Essential Thrombocythemia on Anagrelide Treatment.
34. PDGF-A, PDGF-B, TGF?, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide
35. Corrigendum: Abnormal proplatelet formation and emperipolesis in cultured human megakaryocytes from gray platelet syndrome patients.
36. Screening for MPLmutations in Essential Thrombocythemia and Primary Myelofibrosis: Normal Mpl Expression and Absence of Constitutive STAT3 and STAT5 Activation in MPLW515L-Positive Platelets.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.